Study Summary
The objective of this study is to assess the safety and efficacy of anti-CD7 CAR T-cells in patients with refractory or relapsed T-lineage acute lymphoblastic leukemia (T-ALL).
Want to learn more about this trial?
Request More InfoInterventions
CAR T-cell therapyBIOLOGICAL
This is a single-centre, phase I study to determine the efficacy and safety of CAR T-cell therapy in patients with high-risk T-ALL, refractory or relapsed T-ALL.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Allen Yeoh Eng Juh | Singapore | Singapore |